Year: 2018
Type: article
Study design: Case Report
Abstract: Anti-tumor necrosis factor alpha (TNF-α) therapies have been a significant advance in the treatment of autoimmune and rheumatologic diseases.Early preclinical and clinical studies of anti-TNF-α therapies emphasized infection and malignancy as serious adverse events associated with these agents. 1 However, subsequent clinical experience has increasingly recognized a rare and seemingly paradoxical risk of autoimmunity with agents targeting the TNF-α pathway, most notably psoriatic eruptions, 2 but also autoimmune processes associated with autoantibody production, including systemic vasculitis and lupus erythematosus.3,4 The development of neurologic diseases in association with anti-TNF-α therapy has been documented in case series and small prospective studies, 5 with the most commonly reported associations being demyelinating diseases of the CNS and peripheral nervous systems.Here, we report a patient who developed anti-NMDA receptor (NMDAR) encephalitis while being treated with adalimumab for Crohn disease.
Authors: Geoffrey P. Noble, Eric Lancaster
Institution: University of Pennsylvania
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,450
OpenAlex ID: W2809745558